RNS Number : 3615Z
Diaceutics PLC
21 May 2021
21 May 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Change of Nominated Adviser
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the appointment of Stifel Nicolaus Europe Limited as Nominated Advisor and Sole Corporate Broker with immediate effect.
Enquiries:
|
Diaceutics PLC
Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer
|
www.diaceutics.com
via Alma PR
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)
Ben Maddison
Stewart Wallace
Nick Adams
|
+44 (0)20 7710 7600
|
|
Alma PR
Caroline Forde
Robyn Fisher
Kieran Breheny
|
+44 (0)20 3405 0205
or [email protected]
|
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
APPURAWRAUUVUAR